ADHD Medication Linked to Lower Risk of Early Death
At a Glance
A review of 19 studies examined ADHD and mortality across more than 15.9 million participants.
People with ADHD had a 70% higher risk of death from any cause than those without the condition.
The analysis found a 90% higher risk of suicide and a 50% higher risk of death from injuries among people with ADHD.
ADHD medication use was associated with a lower risk of death from any cause.
A major review published in JAMA Network Open has found that attention-deficit/hyperactivity disorder (ADHD) is associated with higher mortality risks, while medication used to treat the condition is linked to a lower risk of death from any cause.
Key Statements and Focus Area
Mortality Risk: People with ADHD had a 70% higher hazard of death from any cause than people without the condition, according to the review.
Medication and Survival: ADHD medication use was associated with a lower risk of death from any cause among people with the condition, although the analysis does not establish that medication directly reduces mortality.
Research Implications: The authors say the findings reinforce the importance of supporting people with ADHD in managing health risks and addressing broader factors that contribute to poorer health outcomes.
Researchers from institutions across the United Kingdom reviewed 19 studies published between 2012 and 2025. The studies covered populations in the United States, Canada, Sweden, Taiwan, the United Kingdom, Finland, and Denmark.
Together, the studies included more than 15.9 million participants. Researchers pooled data from 12 studies to compare mortality patterns among people with and without ADHD.
The analysis found that people with ADHD had a 90% higher hazard of death by suicide, a 50% higher hazard of death from intentional or unintentional injuries, and a 30% higher hazard of death from natural causes.
The findings on natural-cause mortality differ from an earlier review that did not find evidence of an increased risk. The authors said the difference may reflect the inclusion of newer studies or variations in the research and estimates used.
The review also found an association between ADHD medication use and lower all-cause mortality. However, it did not distinguish the effects of individual medications, and the researchers cautioned that the findings cannot establish cause and effect.
Differences among the studies may reflect variations in the gender composition of participants, cultural attitudes, healthcare services, and changes in how ADHD has been diagnosed and treated over time.
The authors emphasized that pooled results represent average associations across different populations and research settings, rather than outcomes that necessarily apply to every person with ADHD.
FYI
ADHD is a neurodevelopmental condition that can affect attention, impulse control, and executive functioning, including planning and organizing tasks. Its effects vary from person to person and may influence education, work, relationships, and everyday activities.
The findings highlight an association between ADHD and mortality, but they do not mean that an individual with ADHD will experience a shortened lifespan. The review also does not establish that medication alone accounts for the lower mortality risk observed among treated populations. Treatment decisions should be made with a qualified healthcare professional based on individual needs and circumstances.
